KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Non-Current Liabilities: 2011-2025

Historic Total Non-Current Liabilities for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $459.1 million.

  • Travere Therapeutics' Total Non-Current Liabilities fell 11.47% to $459.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $459.1 million, marking a year-over-year decrease of 11.47%. This contributed to the annual value of $528.3 million for FY2024, which is 8.57% down from last year.
  • Latest data reveals that Travere Therapeutics reported Total Non-Current Liabilities of $459.1 million as of Q3 2025, which was down 10.80% from $514.7 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Total Non-Current Liabilities peaked at $620.3 million during Q4 2022, and registered a low of $358.2 million during Q1 2021.
  • In the last 3 years, Travere Therapeutics' Total Non-Current Liabilities had a median value of $528.3 million in 2024 and averaged $530.4 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 52.65% in 2022, then declined by 11.47% in 2025.
  • Travere Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $407.4 million in 2021, then soared by 52.26% to $620.3 million in 2022, then fell by 6.86% to $577.8 million in 2023, then decreased by 8.57% to $528.3 million in 2024, then decreased by 11.47% to $459.1 million in 2025.
  • Its last three reported values are $459.1 million in Q3 2025, $514.7 million for Q2 2025, and $508.7 million during Q1 2025.